



pharma& Acquires the Global Rights to satraplatin from Dayton Therapeutics

- Acquisition includes all intellectual property and the global rights related to satraplatin
- pharma& intends to pursue potential indications in rare hematologic cancers such as relapsed or refractory primary central nervous system lymphoma (PCNSL)
- Pivotal transaction for pharma&, marking a significant step for its strategic focus on building a targeted research and development pipeline

Vienna, Austria, 17 Jan 2024 – pharmaand GmbH (pharma&) announced today it has entered into an agreement with Dayton Therapeutics AG (Dayton Therapeutics), a Switzerland-based clinical oncology company, to acquire the global rights for satraplatin.

Satraplatin, an investigational agent, is in development to potentially be the world's first approved orally administered precision platinum therapy. Platinum-based medicines have become a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. Satraplatin has been studied as a monotherapy or combination therapy in clinical trials involving a range of solid tumors but has not been widely studied in blood cancers. Recent advances in AI-powered genetic and molecular research modeling have identified potential indications in rare hematologic cancers, including primary central nervous system lymphoma (PCNSL) and T-cell lymphoma, based on sensitivity biomarkers, including the *BCL2* gene mutation and *MTAP* deficiency.^{i,ii} pharma& intends to pursue potential indications in rare hematologic cancers such as relapsed or refractory PCNSL.

“The acquisition of satraplatin is a calculated addition to the pharma& portfolio, which has increasingly focused on hematological and oncology treatments,” said Frank Rotmann, Founder and Managing Director, pharma&. “We are extremely enthusiastic about the opportunity to develop this medicine, with an initial focus on rare hematologic cancers, such as relapsed primary central nervous system lymphoma, where patients often have few treatment options.”

PCNSL is a rare nervous system tumor, predominantly diffuse large B-cell lymphoma, that is a life-threatening, debilitating disease with limited therapeutic options.^{iii,iv} The disease occurs at an incidence of 0.5 per 100,000 person-years, accounting for approximately 4% of all primary brain tumors.^{iv,v} Nearly 30% of patients are refractory to primary treatment, and at least 50% relapse. Limited treatment options are available for patients with relapsed or refractory PCNSL, resulting in a poor prognosis for these patients. The 5-year survival rate of all treated patients is 31%, according to registry data.^{vi}

“Relapsed primary central nervous system lymphoma is a devastating disease with very limited treatment options. I am excited to support pharma&'s clinical development of satraplatin, which holds the promise of an orally available therapy while offering a potentially efficacious treatment with a manageable toxicity profile”, said Benjamin Kasenda, MD, PhD, Senior Consultant Medical Oncologist at the University Hospital Basel, Switzerland, and a renowned expert in primary central nervous system lymphoma treatment. “If clinically proven to be successful, satraplatin could be a major breakthrough for eligible patients in this area of high unmet medical need.”

pharma& looks forward to providing satraplatin development updates in the future.

The terms of the agreement remain confidential.

About pharma&

pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines through an agile and fully integrated business model, guaranteeing the enduring availability, dependability, and quality of essential drugs worldwide that patients and healthcare providers rely on. Over the past five years, pharma& has acquired and integrated 11 medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of development, product and API manufacturing, partner distribution, healthcare provider engagement, distribution and services to patients.

About Dayton Therapeutics AG

Dayton Therapeutics AG is a clinical oncology company that specializes in the identification of compounds for the treatment of new cancer indications with limited therapeutic options. The company is leveraging proprietary oncologist know-how, AI and data mining to develop new drug candidates and identify new disease areas for existing compounds.

To the extent that statements contained in this press release are not descriptions of historical facts regarding pharma&, they are forward-looking statements reflecting management's current beliefs and expectations. Examples of forward-looking statements contained in this press release include, among others, statements regarding our future financial and operating performance, business plans or prospects, including expectations concerning research and development, including the expansion of our development pipeline, and initiating a clinical trial. Such forward-looking statements involve substantial risks and uncertainties that could cause pharma&'s actual results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in clinical development, including the outcome of clinical studies, enrollment, and completion of planned studies. pharma& undertakes no obligation to update or revise any forward-looking statements.

#

pharma& Media Contact:

media@pharmaand.com

i Kalimutho M et al., Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways. *Cancer Chemotherapy Pharmacology*, 2011.

ii Zander T et al., Satraplatin demonstrates high cytotoxic activity in genetically defined lymphoid malignancies. *Anticancer Research*, 2022.

iii https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=46135. Accessed December 2023.

iv Schaff LR, Grommes C. Primary central nervous system lymphoma. *Blood*. 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. PMID: 34699590; PMCID: PMC9437714.

v <https://emedicine.medscape.com/article/1157638overview#:~:text=PCNSL%20occurs%20at%20an%20incidence,in%20patients%20who%20are%20immunocompetent>. Accessed December 2023.

vi [The Diagnosis and Treatment of Primary CNS Lymphoma \(22.06.2018\) \[aerzteblatt.de\]](https://www.aerzteblatt.de/nachrichten/1157638). Accessed December 2023.